Prof.
University of Namur, Department of Pharmacy
Namur, Namur, Belgium
After being graduated in pharmaceutical sciences in 2011, Prof. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015. In 2017 he launched QUALIblood, a Contract Research Organization (CRO) aiming to provide the industries, hospitals, and universities with central laboratory services for blood investigations. His company employs 9 people actively working on pre-clinical, phase-1, phase-2, and phase-3 clinical trials in several pharmaceutical fields. In 2018, he gained an academic position at the University of Namur in Belgium where he teaches pharmacology to student in bachelor and master’s degrees. He also provides continuing education for health professionals, especially for pharmacists and clinical biologists. In 2019, he received the Eberhard F. Mammen Young Investigator Award for his research on the development of a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes.
He has multiple collaborations with academics, hospitals, universities to develop accurate and sensitive biomarkers in hemostasis, serology, oncology and more recently neurology.
The research directed by Prof. Douxfils played a leading role in the establishment of guidelines for the laboratory measurement of DOACs. These recommendations have been used so far by several Expert Societies involved in the field of thrombosis and hemostasis. He also provided his expertise for the development of new medicine and has been actively involved in the discussion and the writing of the regulatory documents for the obtention of the marketing authorization.
Thanks to his translational view of the pharmaceutical and medical device market from basic research to post-marketing pharmacovigilance, his collaborations with key opinion leaders but also with field practitioners, Prof. Jonathan Douxfils puts its expertise and know-how at the services of societal projects aiming to improve the safety and effectiveness of therapeutic agents in order to promote public health.
Tuesday, June 27, 2023
18:30 – 19:30 ET